APA (7th ed.) Citation

I, S., JL, M., SA, H., R, W., R, T., R, L. R., . . . H, M. (2024). Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: A dose-escalation, randomised, controlled, phase 1 trial. The Lancet. Infectious diseases, 24(8), 909. https://doi.org/10.1016/S1473-3099(24)00143-9

Chicago Style (17th ed.) Citation

I, Satti, et al. "Safety of a Controlled Human Infection Model of Tuberculosis with Aerosolised, Live-attenuated Mycobacterium Bovis BCG Versus Intradermal BCG in BCG-naive Adults in the UK: A Dose-escalation, Randomised, Controlled, Phase 1 Trial." The Lancet. Infectious Diseases 24, no. 8 (2024): 909. https://doi.org/10.1016/S1473-3099(24)00143-9.

MLA (9th ed.) Citation

I, Satti, et al. "Safety of a Controlled Human Infection Model of Tuberculosis with Aerosolised, Live-attenuated Mycobacterium Bovis BCG Versus Intradermal BCG in BCG-naive Adults in the UK: A Dose-escalation, Randomised, Controlled, Phase 1 Trial." The Lancet. Infectious Diseases, vol. 24, no. 8, 2024, p. 909, https://doi.org/10.1016/S1473-3099(24)00143-9.